Adverse events138

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 138

Type	Event	Organ system	Group	Affected	At risk
other	COVID-19	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	6	321
other	COVID-19	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	10	616
other	COVID-19	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W	9	91
other	COVID-19	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W	9	90
other	COVID-19	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W	6	91
other	COVID-19	Infections and infestations	Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W	10	100
other	Nasopharyngitis	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	8	321
other	Nasopharyngitis	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	9	616
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W	7	91
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W	5	90
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W	7	91
other	Nasopharyngitis	Infections and infestations	Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W	6	100
other	Upper respiratory tract infection	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	14	321
other	Upper respiratory tract infection	Infections and infestations	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	9	616
other	Upper respiratory tract infection	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W	3	91
other	Upper respiratory tract infection	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W	3	90
other	Upper respiratory tract infection	Infections and infestations	Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W	5	91
other	Upper respiratory tract infection	Infections and infestations	Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W	9	100
other	Headache	Nervous system disorders	Initial Treatment Period (Baseline - Week 16 Predose): Placebo	11	321
other	Headache	Nervous system disorders	Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg	28	616

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03985943/events

API reference For AI assistants

Adverse events138

Sources 3

Read this list from software.